BGT226 is primarily used in cancer research, particularly in the study of solid tumors and hematologic malignancies. It functions as a dual inhibitor of PI3K and mTOR pathways, which are crucial for cell growth and survival. By targeting these pathways, BGT226 helps in understanding the mechanisms of tumor progression and resistance to therapy. It is also explored in preclinical studies for its potential to enhance the efficacy of other anticancer treatments when used in combination. Additionally, BGT226 aids in identifying biomarkers that predict response to PI3K/mTOR inhibition, contributing to personalized cancer therapy strategies.